Agios Pharmaceuticals, Inc. (AGIO) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Regulatory-catalyst biotech with strong momentum: shares are ~18% above the 21-day SMA after a ~21% March move, and management just announced plans to seek U.S. accelerated approval for mitapivat in sickle cell disease and is ramping launches of AQVESME/PYRUKYND with ~$1.2â1.3B cashâoffering multiple potential near-term news bursts to extend the rally.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Severe cash burn ⢠Minimal leverage AGIO is wellâcapitalized with extremely high gross margins and negligible leverage but faces sustained heavy cash burn, large operating losses and negative FCF that undermine nearâterm profitability. #well-capitalizedâ #cash-burnâ
Price Behavior
Key Price Behavior Insights: ⢠Short-term uptrend ⢠Resistance cap ⢠Volatile spike risk Support Level: $27.5â$28.5 Resistance Level: $34.8â$35.2 AGIO is in a short-term uptrend (price > last month SMA) trading ~7% above the last-month average after breaking the lateâMarch cluster, but faces a clear resistance band near $34.8â$35.2 and has shown a volatile spike from ~$29.6 to ~$35.20 that risks a pullback toward support. #watch-resistanceâ
Sentiment & News
Key News Insights: ⢠Mitapivat accelerated ⢠Institutional buying ⢠Shareholder investigations Agios is pursuing U.S. accelerated approval for mitapivat in sickle cell disease while reporting commercial uptake and institutional buying amid shareholder probes and volatile nearâterm share moves. #investor-scrutinyâ
AI Summary
Agios has shifted from a pure R&D burn story to a commercial-stage, event-driven rare-disease company where the core investment hinge is whether mitapivat secures accelerated approval with manageable REMS and drives rapid PYRUKYND revenue growthâif yes, >$1.2B in cash and ~91% gross margins could translate to material upside, but regulatory labeling or weak uptake would likely force spend cuts or dilution.
Description
Agios Pharmaceuticals is a biopharmaceutical company that develops therapies directed at cellular metabolism and related biological pathways. The firm commercializes mitapivat (PYRUKYND), an activator of pyruvate kinase used to treat hemolytic anemias, and is conducting Phase I studies of a second pyruvate kinase activator, AG-946, for similar indications. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 2 | Apr 9 | AGIO | Agios Pharmaceuticals, Inc. | Regulatory-catalyst biotech with strong momentum: shares are ~18% above the 21-day SMA after a ~21% March move, and management just announced plans to seek U.S. accelerated approval for mitapivat in sickle cell disease and is ramping launches of AQVESME/PYRUKYND with ~$1.2â1.3B cashâoffering multiple potential near-term news bursts to extend the rally. | Closed | -6.5% |